№ lp_1_2_02039
File format: docx Character count: 604398 File size: 5748 KB
This document provides a comprehensive evaluation of ceftazidime with avibactam (CAZ-AVI) for treating severe aerobic Gram-negative bacterial infections within the NHS, detailing its clinical impact, costs, and health benefits.
Year: 2021
Region / City: United Kingdom
Subject: Health economics, antimicrobial evaluation
Document type: Final report
Organization / Institution: Centre for Health Economics, University of York; Health Economics and Decision Science, University of Sheffield
Author: Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Jean Hamilton, Ruth Wong, Tushar Srivastava, Harry Hill, Chu Chang Ku, Kate Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods
Target audience: Healthcare professionals, policymakers, researchers
Period of validity: 2016 - ongoing
Approval date: October 2021
Date of last modification: October 2021
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Australian Gram-negative Sepsis Outcome Programme (GnSOP) Annual Report 2020
Year: 2020
Country: Australia
Region: Nationwide
Organisation: Australian Group on Antimicrobial Resistance (AGAR)
Programme: Australian Gram-negative Sepsis Outcome Programme (GnSOP)
Authors: Jan M Bell; Alicia Fajardo Lubian; Sally R Partridge; Thomas Gottlieb; Jonathan Iredell; Denise A Daley; Geoffrey W Coombs
Type of document: Annual surveillance report
Subject: Antimicrobial resistance in gram-negative bloodstream infections
Pathogens studied: Enterobacterales; Escherichia coli; Klebsiella pneumoniae; Enterobacter cloacae complex; Pseudomonas aeruginosa; Acinetobacter species
Sample size: 8,752 isolates
Study period: 1 January to 31 December 2020
Participating laboratories: 30 laboratories
Institutions covered: 49 institutions
Methodology: Automated susceptibility testing; PCR screening; whole genome sequencing
Standards applied: CLSI M100; EUCAST v11.0 (January 2021)
Key focus: Resistance to third-generation cephalosporins; fluoroquinolones; piperacillin-tazobactam; carbapenems; colistin
Carbapenemase genes detected: blaIMP-4; blaGES-5; blaNDM-1; blaNDM-5; blaOXA-48; blaOXA-181; blaIMI-1; blaOXA-23+NDM-1
Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2022
Year: 2022
Region / City: Australia
Topic: Antimicrobial resistance, bloodstream infections, gram-negative pathogens
Document Type: Annual Report
Institution: Australian Group on Antimicrobial Resistance (AGAR)
Authors: Jan M Bell, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan R Iredell, Denise A Daley, Geoffrey W Coombs
Target Audience: Healthcare professionals, researchers, and policy makers in antimicrobial resistance
Date of Approval: 16/11/2023
Date of Last Update: 16/11/2023
Which component of lipopolysaccharide is essential for maintaining outer membrane stability in Gram-negative bacteria and would be absent in a mutant unable to synthesize KDO?
Year: Not specified
Region / City: Not specified
Topic: Bacterial biology, Gram-negative bacteria, Lipopolysaccharides
Document Type: Educational Material
Organization / Institution: Not specified
Author: Not specified
Target Audience: Students or professionals in microbiology
Period of Validity: Not specified
Approval Date: Not specified
Date of Changes: Not specified
In Vitro Antimicrobial Activity of Vinca Alkaloids Coated Green Synthesized Silver Nanoparticles Against Selected Foodborne Gram-negative Pathogen
Year: 2024
Region / City: Global
Topic: Antimicrobial Activity, Silver Nanoparticles, Green Synthesis
Document Type: Research Article
Organization / Institution: Not specified
Author: Not specified
Target Audience: Researchers, Scientists in Biotechnology, Microbiology, and Nanotechnology
Period of Validity: Not applicable
Approval Date: Not specified
Modification Date: Not specified
Supplementary data for Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria
Year: 2009–2017
Region / City: Shenzhen, Hangzhou, California, London, Overland Park, Michigan
Theme: Antimicrobial resistance, Clinical pharmacology
Document type: Supplementary data / Clinical study summary
Institution: Shenzhen Institute of Respiratory Diseases; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University; University of Southern California; AstraZeneca; Pfizer; Forest Laboratories
Authors: Tingting Xu, Yuqi Guo, Yang Ji, Baohong Wang, Kai Zhou
Target audience: Researchers in microbiology and pharmacology
Study population: Adults and children (3 months–90 years), healthy volunteers and patients with infections
Clinical conditions: Cystic fibrosis, complicated urinary tract infections, intra-abdominal infections, neutropenic febrile conditions, systemic infections, ICU patients
Trial phases: I–IV
Interventions: Ceftazidime–avibactam alone or in combination with other antibiotics
Completion dates: 2009–2017
Locations of resistance studies: UK, in vitro assays
Organisms studied: K. pneumoniae
Resistance mechanisms: KPC-3 mutants with amino acid substitutions and insertions
Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: Phase 3 randomized trial (ASSEMBLE)
Year: 2026
Countries involved: China, Greece, India, Malaysia, Mexico, Philippines, Romania, Russian Federation, Thailand, Spain
Study type: Phase 3 randomized clinical trial
Therapeutic area: Infectious diseases, antibacterial therapy
Pathogens: Metallo-β-lactamase-producing Gram-negative bacteria
Interventions: Aztreonam-avibactam, comparator therapy (best available therapy)
Patient population: Adults ≥18 years with serious bacterial infections (cIAI, HAP, VAP, cUTI, BSI)
Enrollment period: Screening to day 45 follow-up
Ethics approval: Local IEC/IRB approvals in all participating countries
Primary endpoints: Clinical and microbiological outcomes at test-of-cure (day 28 ±3)
Secondary endpoints: Safety and tolerability during and after treatment
Authors: George L. Daikos, José Miguel Cisneros, Yehuda Carmeli, Minggui Wang, Chee Loon Leong, Konstantinos Pontikis, Anastasia Anderzhanova, Simin Florescu, Roman Kozlov, Eduardo Rodriguez-Noriega, Mina Psichogiou, Pinyo Rattanaumpawan, Anca Streinu-Cercel, Venkatasubramanian Ramasubramanian, Francis F. Arhin, Halley Rogers, Michele Wible, Joanne Leaney, Daria Jacobson, Rienk Pypstra, Joseph W. Chow
Topics: ceftazidime avibactam Gram-negative